Is molecular profiling for gynaecological cancers worth the cost?
In this era of precision medicine, affordable profiling is essential
Is molecular profiling useful in the management of breast cancer?
The value of genomic testing is being increasingly demonstrated and will evolve over time
Encouraging results with savolitinib in NSCLC with MET exon14 skipping mutations
Overall survival data are in line with those from other MET tyrosine kinase inhibitors and show promise in a tumour subtype with poor prognosis
How can we continue to improve outcomes for our patients with lung cancer?
Advances made in the treatment of advanced lung cancer are now being introduced at earlier stages of disease
How can exosome research improve patient management?
As the literature on exosomes continues to grow in cancer basic science, important questions remain regarding opportunities in the clinic
Can DNA methylation improve prognostic models for glioma?
Results show it may help to define more homogeneous subgroups of patients with grade II–III glioma for more timely and effective cancer care
Two studies explore molecular divergence in gastric cancer
Genomic landscaping suggests molecular divergence between cancer subtypes and across disease stages, but molecular similarities between White and Asian populations
Milestone in hereditary breast cancer: PARP inhibition benefits women with early-stage disease
Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women